FDA EIR - Jubilant Pharmova Limited - December 12, 2018

An FDA "For Cause" inspection of Jubilant Generics Limited in Mysore, India, was conducted from December 10 to December 18, 2018. This inspection was initiated due to concerns about an Active Pharmaceutical Ingredient (API) manufactured at the facility, distributed in the US, containing potentially carcinogenic and mutagenic impurities. The inspection was carried out under the regulatory framework of 7356.002F (Active Pharmaceutical Ingredient Process Inspections) and ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients). The team evaluated five key systems: Quality, Laboratory, Facilities and Equipment, Materials, and Production.The inspection identified twelve significant observations, indicating systemic deficiencies. Key issues included inadequate investigations into unexpected results, deficient validation of analytical methods and cleaning processes for non-dedicated equipment, and poor maintenance and storage of manufacturing and laboratory equipment, posing contamination risks. Further concerns involved inadequate segregation of finished APIs, insufficient control over starting materials from contract manufacturers, and substandard facility maintenance. These findings echoed some issues noted in a previous October 2017 inspection.In response, the Site Head acknowledged these deficiencies, committing to implementing corrections and providing a written response to the FDA within 15 business days. The FDA's recommendation is "Official Action Indicated" (OAI) and a Warning Letter (WL), signaling serious regulatory non-compliance.